Katsevman Gennadiy A, Turner Ryan C, Urhie Ogaga, Voelker Joseph L, Bhatia Sanjay
1Department of Neurosurgery.
2West Virginia University School of Medicine, Morgantown, West Virginia.
J Neurosurg. 2019 Feb 8;132(3):914-920. doi: 10.3171/2018.10.JNS181174. Print 2020 Mar 1.
It is commonly reported that achieving gross-total resection of contrast-enhancing areas in patients with glioblastoma (GBM) improves overall survival. Efforts to achieve an improved resection have included the use of both imaging and pharmacological adjuvants. The authors sought to investigate the role of sodium fluorescein in improving the rates of gross-total resection of GBM and to assess whether patients undergoing resection with fluorescein have improved survival compared to patients undergoing resection without fluorescein.
A retrospective chart review was performed on 57 consecutive patients undergoing 64 surgeries with sodium fluorescein to treat newly diagnosed or recurrent GBMs from May 2014 to June 2017 at a teaching institution. Outcomes were compared to those in patients with GBMs who underwent resection without fluorescein.
Complete or near-total (≥ 98%) resection was achieved in 73% (47/64) of fluorescein cases. Of 42 cases thought not to be amenable to complete resection, 10 procedures (24%) resulted in gross-total resection and 15 (36%) resulted in near-total resection following the use of sodium fluorescein. No patients developed any local or systemic side effects after fluorescein injection. Patients undergoing resection with sodium fluorescein, compared to the non-fluorescein-treated group, had increased rates of gross- or near-total resection (73% vs 53%, respectively; p < 0.05) as well as improved median survival (78 weeks vs 60 weeks, respectively; p < 0.360).
This study is the largest case series to date demonstrating the beneficial effect of utilizing sodium fluorescein as an adjunct in GBM resection. Sodium fluorescein facilitated resection in cases in which it was employed, including dominant-side resections particularly near speech and motor regions. The cohort of patients in which sodium fluorescein was utilized had statistically significantly increased rates of gross- or near-total resection. Additionally, the fluorescein group demonstrated prolonged median survival, although this was not statistically significant. This work demonstrates the promise of an affordable and easy-to-implement strategy for improving rates of total resection of contrast-enhancing areas in patients with GBM.
通常报道称,胶质母细胞瘤(GBM)患者实现增强区域的大体全切可提高总生存期。为实现更好的切除效果所做的努力包括使用影像学和药理学辅助手段。作者旨在研究荧光素钠在提高GBM大体全切率方面的作用,并评估与未使用荧光素进行切除的患者相比,使用荧光素进行切除的患者生存期是否有所改善。
对2014年5月至2017年6月在一家教学机构连续接受64次使用荧光素钠手术治疗新诊断或复发性GBM的57例患者进行回顾性病历审查。将结果与未使用荧光素进行切除的GBM患者的结果进行比较。
73%(47/64)的荧光素病例实现了完全或接近完全(≥98%)切除。在42例被认为无法进行完全切除的病例中,使用荧光素钠后,10例手术(24%)实现了大体全切,15例(36%)实现了接近完全切除。荧光素注射后,没有患者出现任何局部或全身副作用。与未使用荧光素治疗的组相比,使用荧光素钠进行切除的患者大体或接近完全切除率有所提高(分别为73%和53%;p<0.05),中位生存期也有所改善(分别为78周和60周;p<0.360)。
本研究是迄今为止最大的病例系列,证明了使用荧光素钠作为GBM切除辅助手段的有益效果。荧光素钠在使用的病例中促进了切除,包括优势侧切除,特别是在语言和运动区域附近。使用荧光素钠的患者队列中,大体或接近完全切除率在统计学上显著提高。此外,荧光素组的中位生存期延长,尽管这在统计学上不显著。这项工作证明了一种经济实惠且易于实施的策略在提高GBM患者增强区域全切率方面的前景。